Rasmus Praetorius Clausen

Rasmus Praetorius Clausen

Auto-generated profile, based on publicly available information

Rasmus Praetorius Clausen

Department for Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2007 in Molecular Pharmacology
Verified
Journal Article
Open access
PDF file
KEKevin Erreger
Kevin Erreger
MGMatthew T. Geballe
Matthew T. Geballe
AKAnders Skov Kristensen
Anders Skov Kristensen
PCPhilip E. Chen
Philip E. Chen
KHKasper B. Hansen
Kasper B. Hansen
STStephen F. Traynelis
Stephen F. Traynelis
The four N-methyl-d-aspartate (NMDA) receptor NR2 subunits (NR2A-D) have different developmental, anatomical, and functional profiles that allow them to serve different roles in normal and neuropathological situations. Identification of subunit-selective NMDA receptor agonists, antagonists, or modulators could prove to be both valuable pharmacological tools as well as potential new therapeutic agents. We evaluated the potency and efficacy of a wide range of glutamate-like compounds at NR1/NR2A, NR1/NR2B, NR1/NR2C, and NR1/NR2D receptors. Twenty-five of 53 compounds examined exhibited agonist activity at the glutamate binding site of NMDA receptors. Concentration-response relationships were determined for these agonists at each NR2 subunit. We find consistently higher potency at the NR2D subunit for a wide range of dissimilar structures, with (2S,4R)-4-methylglutamate (SYM2081) showing the greatest differential potency between NR2A- and NR2D-containing receptors (46-fold). Analysis of chimeric NR2A/D receptors suggests that enhanced agonist potency for NR2D is controlled by residues in both of the domains (Domain1 and Domain2) that compose the bilobed agonist binding domain. Molecular dynamics (MD) simulations comparing a crystallography-based hydrated NR1/NR2A model with a homology-based NR1/NR2D hydrated model of the agonist binding domains suggest that glutamate exhibits a different binding mode in NR2D compared with NR2A that accommodates a 4-methyl substitution in SYM2081. Mutagenesis of functionally divergent residues supports the conclusions drawn based on the modeling studies. Despite high homology and conserved atomic contact residues within the agonist binding pocket of NR2A and NR2D, glutamate adopts a different binding orientation that could be exploited for the development of subunit selective agonists and competitive antagonists.

1 July 2013 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
KHKasper B. Hansen
Kasper B. Hansen
NTNami Tajima
Nami Tajima
RRRune Risgaard
Rune Risgaard
RPRiley E. Perszyk
Riley E. Perszyk
LJLars Jørgensen
Lars Jørgensen
STStephen F. Traynelis
Stephen F. Traynelis
N-methyl-d-aspartate (NMDA) receptors are ligand-gated ion channels assembled from GluN1 and GluN2 subunits. We used a series of N-hydroxypyrazole-5-glycine (NHP5G) partial agonists at the GluN2 glutamate binding site as tools to study activation of GluN1/GluN2A and GluN1/GluN2D NMDA receptor subtypes. Using two-electrode voltage-clamp electrophysiology, fast-application patch-clamp, and single-channel recordings, we show that propyl- and ethyl-substituted NHP5G agonists have a broad range of agonist efficacies relative to the full agonist glutamate (<1–72%). Crystal structures of the agonist binding domains (ABDs) of GluN2A and GluN2D do not reveal any differences in the overall domain conformation induced by binding of the full agonist glutamate or the partial agonist propyl-NHP5G, which is strikingly different from ABD structures of 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propanoate (AMPA) and kainate receptors bound to full and partial agonists. Subsequent evaluation of relative NHP5G agonist efficacy at GluN2A-GluN2D chimeric subunits implicates the amino-terminal domain (ATD) as a strong determinant of agonist efficacy, suggesting that interdomain interactions between the ABD and the ATD may be a central element in controlling the manner by which agonist binding leads to channel opening. We propose that variation in the overall receptor conformation, which is strongly influenced by the nature of interdomain interactions in resting and active states, mediates differences in agonist efficacy and partial agonism at the GluN2 subunits.

7 April 2009 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
KMKarsten K. Madsen
Karsten K. Madsen
RCRasmus P. Clausen
Rasmus P. Clausen
OLOrla M. Larsson
Orla M. Larsson
PKPovl Krogsgaard‐Larsen
Povl Krogsgaard‐Larsen
ASArne Schousboe
Arne Schousboe
HWH. Steve White
H. Steve White
Inhibition of the GABA transporter subtype GAT1 by the clinically available anti‐epileptic drug tiagabine has proven to be an effective strategy for the treatment of some patients with partial seizures. In 2005, the investigational drug EF1502 was described as possessing activity at both GAT1 and BGT‐1. When combined with the GAT1 selective inhibitor tiagabine, EF1502 was found to possess a synergistic anti‐convulsant action in the Frings audiogenic seizure‐susceptible mouse model of reflex epilepsy. This effect was subsequently attributed to inhibition of BGT‐1. In this study, the anti‐convulsant effect of the GAT2/3 inhibitor SNAP‐5114 was assessed in the Frings audiogenic seizure‐susceptible mouse alone, and in combination with tiagabine and EF1502. The results showed that SNAP‐5114 produced a synergistic anti‐convulsant effect in combination with EF1502 but not when used in combination with tiagabine. These findings support anatomical evidence that GAT2/3 are most likely located at the synapse in close proximity to GAT1; whereas BGT‐1 is located some distance away from the synapse and GAT1 and GAT2/3. Lastly, EF1502 and tiagabine were evaluated alone, and in combination, in the corneal kindled mouse model of partial epilepsy. The results of this evaluation provide further evidence in support of a role for BGT‐1 in the control of seizure activity. In addition, they suggest that the combined inhibition of GAT1 and BGT‐1 may afford some advantage over inhibiting either transporter alone.

1 February 2005 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
RCRasmus P. Clausen
Rasmus P. Clausen
EMEjner K. Moltzen
Ejner K. Moltzen
JPJens Perregaard
Jens Perregaard
SLSibylle M. Lenz
Sibylle M. Lenz
CSConnie Sanchez
Connie Sanchez
PKPovl Krogsgaard-Larsen
Povl Krogsgaard-Larsen

2 July 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
NANathan Absalom
Nathan Absalom
LELaura F. Eghorn
Laura F. Eghorn
IVInge S. Villumsen
Inge S. Villumsen
NKNasiara Karim
Nasiara Karim
TBTina Bay
Tina Bay
PWPetrine Wellendorph
Petrine Wellendorph
γ-Hydroxybutyric acid (GHB) binding to brain-specific high-affinity sites is well-established and proposed to explain both physiological and pharmacological actions. However, the mechanistic links between these lines of data are unknown. To identify molecular targets for specific GHB high-affinity binding, we undertook photolinking studies combined with proteomic analyses and identified several GABA A receptor subunits as possible candidates. A subsequent functional screening of various recombinant GABA A receptors in Xenopus laevis oocytes using the two-electrode voltage clamp technique showed GHB to be a partial agonist at αβδ- but not αβγ-receptors, proving that the δ-subunit is essential for potency and efficacy. GHB showed preference for α4 over α(1,2,6)-subunits and preferably activated α4β1δ (EC 50 = 140 nM) over α4β(2/3)δ (EC 50 = 8.41/1.03 mM). Introduction of a mutation, α4F71L, in α4β1(δ)-receptors completely abolished GHB but not GABA function, indicating nonidentical binding sites. Radioligand binding studies using the specific GHB radioligand [ 3 H]( E , RS )-(6,7,8,9-tetrahydro-5-hydroxy-5 H -benzocyclohept-6-ylidene)acetic acid showed a 39% reduction ( P = 0.0056) in the number of binding sites in α4 KO brain tissue compared with WT controls, corroborating the direct involvement of the α4-subunit in high-affinity GHB binding. Our data link specific GHB forebrain binding sites with α4-containing GABA A receptors and postulate a role for extrasynaptic α4δ-containing GABA A receptors in GHB pharmacology and physiology. This finding will aid in elucidating the molecular mechanisms behind the proposed function of GHB as a neurotransmitter and its unique therapeutic effects in narcolepsy and alcoholism.

1 June 2011 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
BLBrian Lohse
Brian Lohse
JKJesper Kristensen
Jesper Kristensen
LKLine H. Kristensen
Line H. Kristensen
KAKarl Agger
Karl Agger
KHKristian Helin
Kristian Helin
RCRasmus P. Clausen
Rasmus P. Clausen